United Republic of TanzaniaTuberculosis profile
Population  2016 56 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 28 (13–50) 51 (23–90)
Mortality (HIV+TB only) 27 (12–46) 48 (22–83)
Incidence  (includes HIV+TB) 160 (75–275) 287 (136–495)
Incidence (HIV+TB only) 54 (35–78) 98 (63–140)
Incidence (MDR/RR-TB)** 2.6 (0.63–4.6) 4.7 (1.1–8.3)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 4.2 (1.5–6.8) 48 (18–78) 52 (19–85)
Males 4.8 (1.8–7.8) 103 (38–167) 107 (40–175)
Total 9 (3.3–15) 151 (56–246) 160 (75–275)
TB case notifications, 2016  
Total cases notified 65 908
Total new and relapse 64 609
          - % tested with rapid diagnostics at time of diagnosis 8%
          - % with known HIV status 97%
          - % pulmonary 79%
          - % bacteriologically confirmed among pulmonary 54%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 40% (24–86)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.38 (0.14–0.66)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 21 720 34%
          - on antiretroviral therapy 19 814 91%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  830
(420–1 200)
Estimated % of TB cases with MDR/RR-TB 1.3% (0.47–2.1) 6.2% (5.1–7.4)  
% notified tested for rifampicin resistance 13% 58% 9 949
MDR/RR-TB cases tested for resistance to second-line drugs   97
Laboratory-confirmed cases MDR/RR-TB: 196, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 158, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 90% 60 895
Previously treated cases, excluding relapse, registered in 2015 80% 1 292
HIV-positive TB cases registered in 2015 83% 22 675
MDR/RR-TB cases started on second-line treatment in 2014 76% 143
XDR-TB cases started on second-line treatment in 2014 0% 1
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 9%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
31% (28–34)
TB financing, 2017  
National TB budget (US$ millions) 70
Funding source: 3% domestic, 39% international, 58% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-15 Data: www.who.int/tb/data